Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$3.2 million.

  • Monte Rosa Therapeutics' Tax Provisions fell 457464.79% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 15885.29%. This contributed to the annual value of $2.6 million for FY2024, which is 66923.08% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Tax Provisions stood at -$3.2 million, which was down 457464.79% from $1.2 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Tax Provisions' 5-year high stood at $2.2 million during Q4 2024, with a 5-year trough of -$3.2 million in Q3 2025.
  • Moreover, its 3-year median value for Tax Provisions was $180000.0 (2023), whereas its average is $179900.0.
  • In the last 5 years, Monte Rosa Therapeutics' Tax Provisions surged by 1007272.73% in 2024 and then crashed by 457464.79% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Tax Provisions stood at -$22000.0 in 2023, then soared by 10072.73% to $2.2 million in 2024, then crashed by 244.8% to -$3.2 million in 2025.
  • Its Tax Provisions stands at -$3.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $822000.0 for Q1 2025.